RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Medipix (the chip for X-ray scanners)

Product
Developers: MARS Bioimaging
Date of the premiere of the system: July, 2018
Branches: Pharmaceutics, medicine, health care

2018: It is started first-ever color 3D - X-ray

In July, 2018 the New Zealand company MARS Bioimaging provided and announced use first-ever color three-dimensional X-ray scanner. It is created on the basis of the Medipix3 technology developed in the European Organization for Nuclear Research (CERN) — the world's largest laboratory of high energy physics. The father and the son, scientists Phil Butler and Anthony Butler from the Universities of Canterbury and Otago spent ten years for development of this medical scanner.

Medipix is family of chips for detection and image processing of particles. This technology allows to receive high-contrast and very exact images and was originally used for tracking of particles on the Large Hadron Collider. However the huge capacity of Medipix allows to use it in different spheres, in particular in medical area.

Began to use the first-ever color 3D - X-ray the device

MARS Bioimaging in cooperation with research institutes developed third generation of chips of Medipix. The powerful algorithms involved in the new bioscanner allow to use information recorded by Medipix3 for generation of three-dimensional images. Different colors of 3D models reflect different levels of energy of the x-ray photons registered by the detector that allows to identify fabrics and also to reveal markers of diseases.

The mini-version of the scanner was already tested as means of detection of cancer, for assessment of a status of bones and joints and also for diagnosis of cardiovascular diseases. Professor Anthony Butler notes that results of prospektivny researches show higher accuracy of diagnostics when using spectral visualization, and it, in turn, allows to accelerate and personalize treatment.

In the second half of 2018 the bioscanner will come to orthopedic and rheumatologic clinics of New Zealand for assessment of its efficiency in real clinical conditions.[1]

Notes